Drew Moghanaki, Chief Medical Officer at Respirati, shared a post on X:
“UCLA’s Jonathan Goldman is scheduled to take the stage at WCLC25 to present the results from the phase 3 HARMONi study demonstrating the benefit of Ivonescimab in 2L for pts progressing through osimertinib with little to no more side effects!”
More posts featuring Drew Moghanaki on OncoDaily.
